Retigabine as add-on treatment of refractory epilepsy - a cost-utility study in a Swedish setting

Acta Neurologica Scandinavica

Volumn 127, Issue 6, 2013, Pages 419-426

  Kristian, B ^a   Wachtmeister, K ^b   Stefan, F ^b   Forsgren, L ^c  

^a LUND UNIVERSITY   (Sweden)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UMEÅ UNIVERSITY   (Sweden)

Author keywords

Add on treatment; Cost effectiveness; Epilepsy; Retigabine

Indexed keywords

HARKOSERIDE; RETIGABINE;

ADD ON THERAPY; ADULT; ARTICLE; ATAXIA; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION TREE; DIZZINESS; FATIGUE; FEMALE; FOCAL EPILEPSY; FOLLOW UP; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; NAUSEA; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOMNOLENCE;

ACETAMIDES; ADULT; ANTICONVULSANTS; CARBAMATES; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; HEALTH CARE COSTS; HUMANS; PHENYLENEDIAMINES; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; SWEDEN;

EID: 84877924371     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12077     Document Type: Article

References (29)

1. Brodie M, Lerche H, Gil-Nagel A et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 2010;75:1817-24.
2. Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 2007;68:1197-204.
3. Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010;51:958-67.
4. Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50:443-53.
5. Ben-Menachem E, Biton V, Jatuzis D, Bou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007;48:1308-17.
6. Wilby J, Kainth A, Hawkins N et al. Clinical effectiveness, tolerability and cost effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess 2005;9:15.
7. Beghi E, Atzeni L, Garattini L. Economic analysis of newer antiepileptic drugs. CNS Drugs 2008;22:861-75.
8. Bolin K, Berggren F, Forsgren L. Lacosamide as treatment of epileptic seizures - cost-utility results for Sweden. Acta Neurol Scand 2010;121:406-12.
9. Bolin K, Forsgren L. The Cost effectiveness of newer treatments for partial-onset seizures - a review of the literature. Pharmacoeconomics 2012;30:903-23.
10. Simoens S, De Naeyer L, Dedeken P. Cost effectiveness of Lacosamide in the adjunctive treatment of patients with refractory focal epilepsy in Belgium. CNS Drugs 2012;26:337-50.
11. Drummond M, Barbieri M, Cook J et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force Report. Value Health 2009;12:409-18.
12. Liou HH, Chen RC, Chen CC, Chiu MJ, Chang YY, Wang JD. Health related quality of life in adult patients with epilepsy compared with a general reference population in Taiwan. Epilepsy Res 2005;64:151-9.
13. Gauffin H, Raty L, Söderfeldt B. Medical outcome in epilepsy patients of young adulthood - a 5-year follow-up study. Seizure 2009;18:293-7.
14. Strzelczyk A, Reese JP, Dodel R, Hamer HM. Cost of epilepsy - a systematic review. Pharmacoeconomics 2008;26:463-76.
15. Pugliatti M, Beghi E, Forsgren L, Ekman M, Sobocki P. Estimating the cost epilepsy in Europe: a review with economic modeling. Epilepsia 2007;48:2224-33.
16. Briggs A, Sculpher M, Claxton K. Decision Modelling for health Economic Evaluation. Oxford University Press: Handbooks in Health Economic Evaluation, 2006.
17. Knoester PD, Deckers CLP, Termeer EH et al. A cost-effectiveness decision model for antiepileptic drug treatment in newly diagnosed epilepsy patients. Value Health 2007;10:173-82.
18. Hawkins N, Epstein D, Drummond M et al. Assessing the cost-effectiveness of new pharmaceuticals in epilepsy in adults: the results of a probabilistic decision model. Med Decis Making 2005;25:493-510.
19. Martyn-St James M, Glanville J, McCool R et al. The efficacy and safety of retigabine and other adjunctive treatments for refractory partial epilepsy: a systematic review and indirect comparison. Seizure 2012;21:665-78.
20. French JA, Abou-Khalil BW, Leroy RF et al. Retigabine (ezogabine) efficacy and safety trial for partial onset epilepsy (RESTORE 1): double-blind, randomised, placebo-controlled trial of retigabine 1200 mg/day as adjunctive therapy in adults with partial-onset seizures. Neurology 2011;76:1555-63.
21. Bolin K, Mörk A-C, Willers S, Lindgren B. Varenicline as compared to bupropion in smoking cessation therapy - cost-utility results for Sweden. Respir Med 2008;102:699-710.
22. Messori A, Trippoli S, Becagli P, Cincotta M, Labbate MG, Zaccara G. Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis. Eur J Clin Pharmacol 1998;53:421-7.
23. Vera-Llonch M, Brandenburg NA, Oster G. Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy. Epilepsia 2008;49:431-7.
24. Craig D, Rice S, Paton F, Fox D, Woolacott N. Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation. A Single Technology Appraisal. Centre for Reviews and Dissemination and Centre for Health Economics, 2011.
25. Fenwick E, O'Brien B, Briggs A. Cost-effectiveness acceptability curves - facts, fallacies and frequently asked questions. Health Econ 2004;13:405-15.
26. Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2010;19:422-37.
27. Bobinac A, van Exel NJA, Rutten FFH, Brouwer WBF. Willingness to pay for a quality-adjusted life-year: the individual perspective. Value Health 2010;13:1046-55.
28. Ivanova JI, Birnbaum HG, Kidolezi Y, Qiu Y, Mallett D, Calleo S. Economic burden of epilepsy among the privately insured in the US. Pharmacoeconomics 2010;28:675-85.
29. Ivanova JI, Birnbaum HG, Kidolezi Y, Qiu Y, Mallett D, Calleo S. Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States. Epilepsia 2010;51:838-44.